Abstract:Objective To investigate the clinical effect of antiplatelet combined with anticoagulant drugs on patients with coronary heart disease complicated with lower limb artery occlusion.Methods A total of 104 patients with coronary heart disease combined with treatment in hospitalization in Fushun City Hospital of Traditional Chinese Medicine from January 2019 to December 2020.According to random number table method,they were divided into monoclonal antibody group (n=52) and double antibody group (n=52).Both groups received routine examination and basic treatment after admission.In addition to the basic treatment,the monoclonal antibody group was given Aspirin enteric-coated tablet,and the double antibody group was given Rivaroxaban tablet in addition to the monoclonal antibody group.The intervention lasted for 8 weeks in both groups.The Seattle Scale (SAQ) score,treatment effect of lower extremity arteriosclastic oblusion,quality of life score (SF-36),ankle-brachial index (ABI),activated partial thrombin time (APTT),prothrombin time (PT) and platelet (PLT) were compared between two groups before and after treatment.Results There was no significant difference in SAQ score between the two groups before and after treatment (P>0.05).There was no significant difference in ABI between the two groups before treatment (P>0.05).After treatment,the ABI of the two groups was higher than before,and the ABI of the double antibody group was higher than that of the monoclonal antibody group,the differences were statistically significant (P<0.05).There was no significant difference in SF-36 score before treatment (P>0.05).After treatment,the SF-36 score of the two groups were higher than those before treatment,and the SF-36 score of the double antibody group was higher than that of the monoclonal antibody group,the differences were statistically significant (P<0.05).There were no significant differences in APTT,PT and PLT between two groups before and after treatment (P>0.05).Conclusion Aspirin combined with Rivaroxaban treatment of coronary heart disease combined with lower extremity arteriosclerosis can be brought to thrombin to form a thrombosis,thereby improving the treatment of patients to improve the patient′s ABI level.
白森. 抗血小板联合抗凝药物治疗冠心病合并下肢动脉闭塞的临床效果[J]. 中国当代医药, 2022, 29(3): 17-20转24.
BAI Sen. Clinical effect of antiplatelet combined with anticoagulant in the treatment of coronary heart disease complicated with lower limb arterial occlusion. 中国当代医药, 2022, 29(3): 17-20转24.
Rajpurkar M,Zia A,Weyand AC,et al.Management of anticoagulation associated reproductive tract bleeding in adolescent and young adult females-Results of a multinational survey[J].Thromb Res,2021,203:63-68.
De Vriese AS,Caluwé R,Van Der Meersch H,et al.Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation:A Multicenter Randomized Controlled Trial[J].J Am Soc Nephrol,2021,32(6):1474-1483.